Market Highlights:
Global Myasthenia Gravis Disease Market Research Report: Diagnosis (Imaging, Blood Tests, Electrodiagnostic, Edrophonium Test), Treatment (Medication, Surgery, HSCT), End-User (Hospitals, Clinics, Academic Research Institutes) – Global Forecast Till 2027
Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking. As per a study conducted by the Myasthenia Gravis Foundation of America, myasthenia gravis is the most common type of neuromuscular disorder. It is a rare condition with a prevalence of 14 to 20 cases per 100,000 people in the United States.
The global market for the myasthenia gravis disease is expected to grow approximately at a CAGR of 7.5% during 2017 to 2023.
Key Players:
Some of the key players in the global myasthenia gravis disease market are Valeant Pharmaceuticals International (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), Teva Pharmaceutical Industries Ltd. (Israel), RPG Life Sciences (India), Cipla (India), F. Hoffmann Roche La Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Biogen Inc. (U.S.), and AbbVie Inc. (U.S.), GlaxoSmithKline plc (UK), Fresenius Kabi (Germany), and others.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/5843
Segmentation:
The global myasthenia gravis disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium test, pulmonary function test, and others. The imaging segment is classified into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.
On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others.
The medication segment is divided into acetylcholinesterase inhibitors, immunosuppressant drugs, steroids, and others. The acetylcholinesterase inhibitors are classified into atropine, neostigmine, pyridostigmine, and others. The immunosuppressant drugs are further divided into prednisone, azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids are further divided into prednisone and others. The surgery is finally divided into thymectomy and others.
On the basis of end-user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.
Regional Analysis:
The global myasthenia gravis disease market consists of regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominates the global myasthenia gravis disease market owing to the growing prevalence of muscular dystrophies such as congenital muscular dystrophies, distal muscular dystrophy, Becker muscular dystrophies, and others along with the extensive demand for diagnostic and treatment services. Moreover, major companies are launching FDA approved drugs thus increasing the commercial access to these drugs worldwide.
The European region is the second largest market for the global myasthenia gravis disease owing to the adoption of new therapies, skilled medical professionals, and availability of advanced treatment facilities. According to the National Institute of Neurological Disorders and Stroke (NINDS), an estimated 15 cases of myasthenia gravis occurs per 100,000 people in the United Kingdom every year.
The Asia Pacific market is the fastest growing therapeutic market owing to the large aging population in countries such as Japan and China coupled with the rising awareness about the long-term effects of muscular dystrophies. Moreover, the cumulative initiatives of the World Health Organization (WHO) in countries such as Japan, China, and India are likely to foster the strengthening of major Asian countries in the future. The Middle East and Africa is likely to exhibit steady growth in this market due to the demand for drugs in remote areas and increasing prevalence of neurological diseases.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
